16 patents
Utility
Methods for treating cancer
2 Jan 24
Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus).
Gary Hattersley
Filed: 25 Oct 21
Utility
Abaloparatide formulations and methods of testing, storing, modifying, and using same
5 Dec 23
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 21 Oct 22
Utility
Methods for treating cancer
21 Nov 23
Fiona Garner, Gary Hattersley
Filed: 4 Aug 20
Utility
Process of making abaloparatide
7 Nov 23
Disclosed herein is an improved process for preparing abaloparatide.
Matt Burke, Silvio Campagna
Filed: 19 May 23
Utility
Abaloparatide formulations and methods of testing, storing, modifying, and using same
10 Oct 23
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 1 Apr 21
Utility
Polymorphic forms of RAD1901-2HCL
25 Jul 23
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 14 Sep 21
Utility
Polymorphic forms of RAD1901-2HCl
9 May 23
A solid form of RAD1901-2HCl having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2θ±0.2 degrees 2θ, and compositions, methods, and processes thereof.
Michael Paul Cruskie, Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 3 Jul 19
Utility
Methods for treating cancer
16 Aug 22
Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.
Gary Hattersley
Filed: 24 Sep 19
Utility
Estrogen receptor-modulating compounds
12 Jul 22
Described herein are compounds that are estrogen receptor modulators.
Chris Miller
Filed: 22 Jan 19
Utility
Stable cannabinoid formulations
17 May 22
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
Filed: 31 Jul 15
Utility
Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
22 Feb 22
The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample.
Heidi K. Chandler
Filed: 7 Jul 21
Utility
Stable cannabinoid formulations
18 Jan 22
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
Filed: 28 May 15
Utility
Polymorphic forms of RAD1901-2HCL
19 Oct 21
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 6 Jul 20
Utility
Abaloparatide formulations and methods of testing, storing, modifying, and using same
4 May 21
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 28 Aug 19
Utility
Polymorphic forms of RAD1901-2HCl
17 Aug 20
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 12 Sep 19
Utility
Formulations of abaloparatide, transdermal patches thereof, and uses thereof
24 Feb 20
Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
Filed: 5 Apr 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first